BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, December 28, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 25, 2018

View Archived Issues

Metabolic remodeling seen during liver regeneration

Read More

New Tau tracer [18F]S16 distinguishes patients with Alzheimer's disease from healthy controls

Read More

Long noncoding RNA CALM3-AS1 acts as a microRNA sponge to promote bladder cancer progression

Read More

Metastasis and self-renewal of group 3 medulloblastomas is driven by NOTCH1

Read More

DeltaNp63 promotes metastasis in triple-negative breast cancer

Read More

Exome sequencing reveals SLC20A1 to be a possible cause of cloacal and bladder exstrophy

Read More

Familial association of a variant in MEGF6 with osteoporosis

Read More

MDM2/p53 inhibitor PM-2 can radiosensitize p53-expressing tumors

Read More

AQP9 emerges as a candidate gene for keloid development

Read More

Results from the phase IIb RISE-SSc study of riociguat presented

Read More

Oyster Point's OC-01 and OC-02 demonstrate improvement in Schirmer's score for dry eye disease

Read More

China NMPA accepts NDA for zanubrutinib in relapsed/refractory CLL/SLL

Read More

Phase IIb study of SM-04690 in knee osteoarthritis meets primary endpoints

Read More

Takeda Pharmaceutical identifies GPR6 receptor modulators

Read More

Roche and Genentech patent new MAP4K1 inhibitors

Read More

Alexion and Dicerna collaborate on RNAi therapies for complement-mediated diseases

Read More

Inventiva synthesizes YAP-TEAD interaction inhibitors

Read More

Kyoto Pharmaceutical Industries divulges nonsense mutation suppressors

Read More

Janssen and collaborator present new antiviral compounds

Read More

Pfizer opens phase I study of PF-06952229 for advanced solid tumors

Read More

Syntrix enrolling patients for phase II trial of Omnitram for diabetic neuropathy

Read More

Privo opens phase I/II trial of PRV-111 for early-stage oral cancer

Read More

FDA approves Xofluza for influenza

Read More

First patient dosed in study of AXO-Lenti-PD gene therapy for Parkinson's disease

Read More

Growth hormone deficiency caused by homozygous GH1 deletion

Read More

Whole exome sequencing of Tunisian patients with ataxia further expands the known causative genes

Read More

Confirmatory phase III study of Talicia for H. pylori infection completes final patient assessment

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Businessman, businesswoman handshake

    Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

    BioWorld
    Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing